Integra Lifesciences Hldgs Cp SEC Filings

Integra LifeSciences Holdings Corp executive Michael Damon Hutchinson filed an initial ownership report showing no securities beneficially owned. The Form 3 identifies him as EVP, Chief Legal Officer and Secretary of Integra LifeSciences, and confirms that, as of the event date, he did not hold any direct or indirect equity or derivative securities of the company.

Integra LifeSciences Holdings Corp President & CEO Mojdeh Poul reported routine equity compensation activity. On January 6, 2026, 848 and 542 shares of common stock were acquired at $0 per share upon the vesting and settlement of corresponding restricted stock units.

On the same date, 848 and 542 common shares were disposed of at $13.13 per share in transactions coded "F", reflecting shares withheld or sold to cover taxes. Following these transactions, the report shows no directly held common stock, while Ms. Poul continues to hold restricted stock unit awards, with post-transaction amounts reported as 102,840 and 102,298 units in two separate grants. A footnote explains that these awards vest in three equal annual installments starting January 6, 2026 and are scheduled for deferred delivery after her separation from service.

Integra LifeSciences Holdings Corporation adopted a renewed change in control severance program for certain senior executives, effective January 1, 2026. The program applies if an executive is terminated without cause or resigns for good reason within two years after a change in control that occurs by December 31, 2026.

Covered leaders include CFO Lea Knight and business presidents Robert T. Davis, Jr., Michael McBreen, and Harvinder Singh. On a qualifying termination, they may receive a lump sum of 1.5 times their salary plus target bonus, or 2 times for Ms. Knight, a pro rata target bonus for the year of termination, subsidized COBRA premiums for up to 18 months, up to 12 months of outplacement services, and any earned but unpaid prior-year bonus. Benefits require a release of claims and are subject to a “best pay cap” that can reduce payments to mitigate excise taxes. The program runs through December 31, 2026, with automatic extensions after a change in control or qualifying termination until all obligations are met.

Integra LifeSciences (IART) director Jeffrey Alan Graves reported an open‑market purchase of 9,000 shares on 11/05/2025 at $11.35 per share.

Following the transaction, he beneficially owns 41,086 shares, held directly. The report was filed as a Form 4 and signed by an attorney‑in‑fact.

Integra LifeSciences (IART) reported Q3 2025 results. Net revenue was $402,062, up from $380,834 a year ago. Operating income was $11,761 versus a loss in the prior year quarter, while net loss narrowed to $5,404 from $10,695.

Year to date, results reflect a non‑cash goodwill impairment of $511,365 recorded in Q2, driving a nine‑month net loss of $514,770. Segment mix showed strength in Codman Specialty Surgical at $292,583, led by Neurosurgery $201,563 and ENT $40,869; Tissue Technologies was $109,479.

On the balance sheet, cash and cash equivalents were $232,186 as of September 30, 2025. The company repaid convertible debt during the period, with “Convertible securities” at $0 versus $573,170 at year‑end, and long‑term borrowings under the senior credit facility rose to $1,708,851. Inventories increased to $489,106. Cash from operations for the nine months was $38,568. Shares outstanding were 77,892,111 as of October 29, 2025.

Integra LifeSciences (IART) furnished an update on results for the quarter ended September 30, 2025 via a press release attached as Exhibit 99.1. The release includes reconciliations between GAAP and non-GAAP measures such as organic revenues, adjusted EBITDA, adjusted net income, adjusted gross profit, adjusted gross margin, adjusted earnings per diluted share, net debt, free cash flow, and adjusted free cash flow conversion for comparable periods in 2025 and 2024.

The company also provided forward-looking guidance for adjusted earnings per diluted share and did not reconcile it to GAAP EPS because certain expense items are highly variable and not reasonably predictable. Non-GAAP adjustments may include structural optimization, acquisition/divestiture and integration-related costs, EU Medical Device Regulation costs, charges related to the prior Boston manufacturing recall and Braintree transition, intangible amortization, tax effects of adjustments, and impairment charges.

Integra LifeSciences (IART) reported an insider equity event. EVP & President, International Harvinder Singh vested 11,965 restricted stock units on 10/12/2025, which settled into common stock. To cover taxes, 3,281 shares were withheld at $13.34, and the reporting person retained 8,684 shares from the vesting. Following these transactions, direct beneficial ownership stood at 21,936 common shares.

The RSU award vested in full on the third anniversary of its grant date (10/12/2022). Derivative securities beneficially owned following the event were 22,566 RSUs.

Chantal Veillon-Berteloot, EVP & CHRO of Integra LifeSciences Holdings Corp (IART), reported two sales of company common stock on 09/01/2025. The filing shows a disposition of 2,139 shares at $15.13, leaving 29,059 shares beneficially owned after that transaction, and a separate disposition of 1,412 shares at $15.13, leaving 27,647 shares beneficially owned after that transaction.

The Form 4 is signed by an attorney-in-fact and includes a Power of Attorney exhibit; it documents insider selling and fulfills disclosure requirements under Section 16.

Integra LifeSciences (IART) Form 4: Director Stuart Essig reported multiple internal transfers of common stock in August 2025. On August 14, 2025 he transferred 200,000 shares to a grantor trust for which his spouse is trustee and received assets of equal fair market value. The same date shows a 200,000-share acquisition entry at $13.62 and a 200,000-share disposition at $13.62 reflecting the trust transfer. Prior to that, on August 8, 2025, 180,080 shares were distributed to Essig from GRAT E as an annuity payment and 500,000 shares were distributed from GRAT F as an annuity payment; GRAT F was then terminated because remaining shares were insufficient to satisfy the annuity obligation. Following the reported transactions, the filings list 1,152,236 shares beneficially owned directly and various indirect holdings through trusts (including 219,920 by GRAT E and 213,115 by a family trust).